UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response

The lancet oncology, 2014-09, Vol.15 (10), p.1137-1146

2014

Volltextzugriff (PDF)

Primary results from CECILIA, a global single-arm phase II study evaluating bevacizumab, carboplatin and paclitaxel for advanced cervical cancer

Gynecologic oncology, 2020-10, Vol.159 (1), p.142-149

2020

Volltextzugriff (PDF)

Pattern of Rash, Diarrhea, and Hepatic Toxicities Secondary to Lapatinib and Their Association With Age and Response to Neoadjuvant Therapy: Analysis From the NeoALTTO Trial

Journal of clinical oncology, 2013-12, Vol.31 (36), p.4504-4511

2013

Volltextzugriff (PDF)

Multidisciplinary management of clear-cell renal cell carcinoma in Africa and the Middle East: current practice and recommendations for improvement

Journal of multidisciplinary healthcare, 2015-01, Vol.8 (default), p.335-344

2015

Volltextzugriff (PDF)

Geoffrey Falkson, 9 August 1932 - 10 January 2019

South African medical journal, 2019-03, Vol.109 (3), p.137-137

Dreosti, Lydia Mary

2019

Volltextzugriff (PDF)

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

The Lancet (British edition), 2019-05, Vol.393 (10183), p.1819-1830

2019

Volltextzugriff (PDF)

A Postauthorization Survey to Document the Therapeutic Management of Oxaliplatin as a First-Line Chemotherapy Regimen in South Africa in Patients with Metastatic Colorectal Cancer

Chemotherapy Research and Practice, 2014-01, Vol.2014 (2014), p.e1-8

2014

Volltextzugriff (PDF)

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

The Lancet (British edition), 2018-07, Vol.392 (10142), p.123-133

2018

Volltextzugriff (PDF)

Geoffrey Falkson, 9 August 1932 - 10 January 2019

SAMJ: South African Medical Journal, 2019-03, Vol.109 (3), p.137-137

Dreosti, Lydia Mary

2019

Volltextzugriff (PDF)

Insights into the epidemiology of renal cell carcinoma in North Africa and the Middle East

Journal de la faculté de médecine d'Oran (En ligne), 2024-08, Vol.1 (2)

2024

Volltextzugriff (PDF)

Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: Phase II randomized study in women with endocrine-therapy-naïve advanced breast cancer

Breast cancer research and treatment, 2016-11, Vol.160 (1), p.91-99

2016

Volltextzugriff (PDF)

A Post-Authorization Survey Documenting the Therapeutic Management of Oxaliplatin as First-Line Chemotherapy in South African Patients with Metastatic Colorectal Cancer

Annals of oncology, 2013-06, Vol.24, p.iv104-iv104

2013

Volltextzugriff (PDF)

Preliminary results from CECILIA, an open-label global safety study of bevacizumab (BEV), carboplatin (C) and paclitaxel (P) therapy for metastatic, recurrent or persistent cervical cancer (CC)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.5528-5528

2018

Volltextzugriff (PDF)

Survival of patients with Kaposi sarcoma in the South African antiretroviral treatment era: a retrospective cohort study

South African medical journal, 2017-09, Vol.107 (10), p.871-876

2017

Volltextzugriff (PDF)

Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients

European journal of cancer (1990), 2017-09, Vol.82, p.237-246

2017

Volltextzugriff (PDF)

Insights into the epidemiology of renal cell carcinoma in North Africa and the Middle East

Journal de la faculté de médecine d'Oran (En ligne), 2022-04, Vol.1 (2)

2022

Volltextzugriff (PDF)

Extended survival analysis of ipilimumab for the treatment of advanced malignant melanoma in pretreated patients: Five-year long-term follow-up of the South African expanded access program

Journal of clinical oncology, 2017-03, Vol.35 (7_suppl), p.84-84

2017

Volltextzugriff (PDF)

Insights into the epidemiology of renal cell carcinoma in North Africa and the Middle East

Journal de la faculté de médecine d'Oran (En ligne), 2017-06, Vol.1 (2)

2017

Volltextzugriff (PDF)

Avelumab (MSB0010718C; anti-PD-L1) vs platinum-based doublet as first-line treatment for metastatic or recurrent PD-L1-positive non-small-cell lung cancer: The phase 3 JAVELIN Lung 100 trial

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.TPS9105-TPS9105

2016

Volltextzugriff (PDF)

Efficacy and safety of the proposed bevacizumab biosimilar BAT1706 compared with reference bevacizumab in patients with advanced nonsquamous non‐small cell lung cancer: A randomized, double‐blind, phase III study

Cancer medicine (Malden, MA), 2023-11, Vol.12 (22), p.20847-20863

2023

Volltextzugriff (PDF)

1 – 25 von 34

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(32)
Mit Volltextzugriff
(33)

Publikationsform

Artikel
(34)

Sprache

Englisch
(33)
Portugiesisch
(1)

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response

Primary results from CECILIA, a global single-arm phase II study evaluating bevacizumab, carboplatin and paclitaxel for advanced cervical cancer

Pattern of Rash, Diarrhea, and Hepatic Toxicities Secondary to Lapatinib and Their Association With Age and Response to Neoadjuvant Therapy: Analysis From the NeoALTTO Trial

Multidisciplinary management of clear-cell renal cell carcinoma in Africa and the Middle East: current practice and recommendations for improvement

Geoffrey Falkson, 9 August 1932 - 10 January 2019

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

A Postauthorization Survey to Document the Therapeutic Management of Oxaliplatin as a First-Line Chemotherapy Regimen in South Africa in Patients with Metastatic Colorectal Cancer

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

Geoffrey Falkson, 9 August 1932 - 10 January 2019

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

Insights into the epidemiology of renal cell carcinoma in North Africa and the Middle East

Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study

Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: Phase II randomized study in women with endocrine-therapy-naïve advanced breast cancer

A Post-Authorization Survey Documenting the Therapeutic Management of Oxaliplatin as First-Line Chemotherapy in South African Patients with Metastatic Colorectal Cancer

Preliminary results from CECILIA, an open-label global safety study of bevacizumab (BEV), carboplatin (C) and paclitaxel (P) therapy for metastatic, recurrent or persistent cervical cancer (CC)

Survival of patients with Kaposi sarcoma in the South African antiretroviral treatment era: a retrospective cohort study

Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients

Insights into the epidemiology of renal cell carcinoma in North Africa and the Middle East

Treatment Patterns and Clinical Outcomes in Patients with Hodgkin Lymphoma from Saudi Arabia, Türkiye, and South Africa: Subgroup Analysis from the International, Multi-center, Retrospective BHOLISTIC Study

Extended survival analysis of ipilimumab for the treatment of advanced malignant melanoma in pretreated patients: Five-year long-term follow-up of the South African expanded access program

Insights into the epidemiology of renal cell carcinoma in North Africa and the Middle East

Avelumab (MSB0010718C; anti-PD-L1) vs platinum-based doublet as first-line treatment for metastatic or recurrent PD-L1-positive non-small-cell lung cancer: The phase 3 JAVELIN Lung 100 trial

Efficacy and safety of the proposed bevacizumab biosimilar BAT1706 compared with reference bevacizumab in patients with advanced nonsquamous non‐small cell lung cancer: A randomized, double‐blind, phase III study

Serum Biomarkers Predict Outcomes in Advanced Hodgkin Lymphoma Independent of International Prognostic Score (IPS) and Treatment: Correlative Analysis from a Large North American Cooperative Group Trial

Suchergebnisse filtern